TILVANCE-301, a Phase 3, multicenter, randomized, open-label, parallel-group, multicenter, international study to assess the efficacy and safety of lifileucel in combination with pembrolizumab in patients with unresectable or metastatic melanoma (Figure 1 and Figure 2) ~670 patients will be randomized 1:1 to either Arm A (lifileucel plus pembrolizumab) or Arm B (pembrolizumab alone). Patients randomized to Arm B who receive pembrolizumab ~670 patients will be randomized 1:1 to either Arm A (lifileucel plus pembrolizumab) or Arm B (pembrolizumab alone). Patients randomized to Arm B who receive pembrolizumab...